Nipro newsletter April 2026
tjoapck banner – feb 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Merxin March 2026
Chemspec Feb 2026
the bridge – website ad 28/01/2026
Terumo 05/01
SAE Media – pre-filled syringes – East Coast 19/11/25
SAE Media – Pre-filled syringes West Coast 19/11/25
Nipro April 2026

JCVI does not recommend COVID-19 vaccination for all 12 to 15-year-olds

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) announced last Friday (3rd September) that it does not recommend universal COVID-19 vaccination for healthy 12 to 15-year-olds ‘at this time’.

According to the JCVI, although the health benefits from COVID-19 vaccinations are marginally greater than the potential known harms, this margin of benefit is ‘too small’ to recommend vaccinations for this age group currently.

The JCVI added that considering the wider societal impacts of vaccination – including educational benefits – are outside its remit.

As such, the JCVI said the government may wish to seek further input on the wider impacts of vaccination in this age group from the UK’s chief medical officer.

The Department of Health and Social Care has since announced that the four chief medical officers will provide further advice on the vaccination of 12 to -15-year-olds.

The UK’s chief medical officer will launch the process of assessing the wider impact of universal COVID-19 vaccination in this population.

“People aged 12 to 15 who are clinically vulnerable to the virus have already been offered a COVID-19 vaccine, and today we’ll be expanding the offer to those with conditions such as sickle cell disease or type 1 diabetes to protect even more vulnerable children,” said Health and Social Care Secretary Sajid Javid.

“Along with Health Ministers across the four nations, I have today written to the Chief Medical Officers to ask that they consider the vaccination of 12 to 15-year-olds from a broader perspective, as suggested by the JCVI. We will then consider the advice from the Chief Medical Officers, building on the advice from the JCVI, before making a decision shortly,” he added.

SMI London
Biopharma group march 2026
Interpack Staubli March 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025